News
Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
Novo Nordisk’s weight loss drug, Wegovy, is experiencing a surge in new prescriptions following a US ban on its copycat ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Wegovy is designed to be taken once a week by self-injection. Patients start on the lowest dose, 0.25 milligrams, and move up to the maintenance dose, 2.4 milligrams, over the course of 16 weeks.
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback